{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T13:00:41Z","timestamp":1773493241756,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.anai.2021.06.021","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T12:00:22Z","timestamp":1625054422000},"page":"412-419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Treatment of systemic mastocytosis"],"prefix":"10.1016","volume":"127","author":[{"given":"Matthew P.","family":"Giannetti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.anai.2021.06.021_bib0001","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jaci.2018.01.034","article-title":"Mast cells signal their importance in health and disease","volume":"142","author":"Olivera","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2021.06.021_bib0002","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"10.1016\/j.anai.2021.06.021_bib0003","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.anai.2021.06.021_bib0004","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.iac.2014.01.009","article-title":"Molecular defects in mastocytosis: KIT and beyond KIT","volume":"34","author":"Bibi","year":"2014","journal-title":"Immunol Allergy Clin North Am"},{"issue":"4","key":"10.1016\/j.anai.2021.06.021_bib0005","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/bjh.12916","article-title":"Epidemiology of systemic mastocytosis in Denmark","volume":"166","author":"Cohen","year":"2014","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.anai.2021.06.021_bib0006","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast cells, Mastocytosis, and related disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.anai.2021.06.021_bib0007","doi-asserted-by":"crossref","first-page":"10743","DOI":"10.7150\/thno.46719","article-title":"Mast cells as a unique hematopoietic lineage and cell system: from Paul Ehrlich's visions to precision medicine concepts","volume":"10","author":"Valent","year":"2020","journal-title":"Theranostics"},{"issue":"8","key":"10.1016\/j.anai.2021.06.021_bib0008","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.jaip.2020.02.021","article-title":"The utility of measuring urinary metabolites of mast cell mediators in systemic mastocytosis and mast cell activation syndrome","volume":"8","author":"Butterfield","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.anai.2021.06.021_bib0009","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the classification and treatment of mastocytosis: current status and outlook toward the future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.anai.2021.06.021_bib0010","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/00005344-198307000-00004","article-title":"Cardiovascular effects of histamine infusion in man","volume":"5","author":"Vigorito","year":"1983","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"10.1016\/j.anai.2021.06.021_bib0011","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0091-6749(81)90134-2","article-title":"Effects of infused histamine: analysis of the effects of H-1 and H-2 histamine receptor antagonists on cardiovascular and pulmonary responses","volume":"68","author":"Kaliner","year":"1981","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2021.06.021_bib0012","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM200402123500723","article-title":"Leukotriene-receptor inhibition for the treatment of systemic mastocytosis","volume":"350","author":"Tolar","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.anai.2021.06.021_bib0013","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0091-6749(90)90067-E","article-title":"Cromolyn sodium in the management of systemic mastocytosis","volume":"85","author":"Horan","year":"1990","journal-title":"J Allergy Clin Immunol"},{"issue":"1-4","key":"10.1016\/j.anai.2021.06.021_bib0014","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.prostaglandins.2010.03.003","article-title":"Increased leukotriene E4 excretion in systemic mastocytosis","volume":"92","author":"Butterfield","year":"2010","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"3","key":"10.1016\/j.anai.2021.06.021_bib0015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0006-2952(96)00243-2","article-title":"Characterization of the 78 kDa mast cell protein phosphorylated by the antiallergic drug cromolyn and homology to moesin","volume":"52","author":"Correia","year":"1996","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.anai.2021.06.021_bib0016","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2796.1991.tb00379.x","article-title":"A case of systemic mastocytosis; therapeutic efficacy of ketotifen","volume":"229","author":"P\u00f3voa","year":"1991","journal-title":"J Intern Med"},{"issue":"4","key":"10.1016\/j.anai.2021.06.021_bib0017","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/0091-6749(90)90205-I","article-title":"Ketotifen and systemic mastocytosis","volume":"85","author":"Ting","year":"1990","journal-title":"J Allergy Clin Immunol"},{"issue":"3-4","key":"10.1016\/j.anai.2021.06.021_bib0018","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.prostaglandins.2009.01.001","article-title":"Survey of aspirin administration in systemic mastocytosis","volume":"88","author":"Butterfield","year":"2009","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"4","key":"10.1016\/j.anai.2021.06.021_bib0019","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000144042","article-title":"Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production","volume":"147","author":"Butterfield","year":"2008","journal-title":"Int Arch Allergy Immunol"},{"issue":"6","key":"10.1016\/j.anai.2021.06.021_bib0020","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2007.03.032","article-title":"Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis","volume":"119","author":"Carter","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2021.06.021_bib0021","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/all.13237","article-title":"Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations","volume":"73","author":"Broesby-Olsen","year":"2018","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.anai.2021.06.021_bib0022","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.jaip.2019.10.022","article-title":"One-day ultrarush desensitization for Hymenoptera venom anaphylaxis in patients with and without mast cell disorders with adjuvant omalizumab","volume":"8","author":"Giannetti","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2021.06.021_bib0023","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaip.2014.03.009","article-title":"Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report","volume":"2","author":"Sokol","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"13","key":"10.1016\/j.anai.2021.06.021_bib0024","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.anai.2021.06.021_bib0025","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.anai.2021.06.021_bib0026","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2362.2008.02036.x","article-title":"Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis","volume":"38","author":"Aichberger","year":"2008","journal-title":"Eur J Clin Invest"},{"issue":"8","key":"10.1016\/j.anai.2021.06.021_bib0027","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.anai.2021.06.021_bib0028","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/j.leukres.2008.12.020","article-title":"Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis","volume":"33","author":"Vega-Ruiz","year":"2009","journal-title":"Leuk Res"},{"issue":"9383","key":"10.1016\/j.anai.2021.06.021_bib0029","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast-cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.anai.2021.06.021_bib0030","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients","volume":"119","author":"Casassus","year":"2002","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.anai.2021.06.021_bib0031","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jaci.2010.02.019","article-title":"Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms","volume":"125","author":"\u00c1lvarez-Twose","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2021.06.021_bib0032","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/modpathol.2013.117","article-title":"Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis","volume":"27","author":"Berezowska","year":"2014","journal-title":"Mod Pathol"},{"issue":"Supplement 1","key":"10.1016\/j.anai.2021.06.021_bib0033","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-136930","article-title":"Increased Detection of KIT D816V Mutation in Peripheral Blood Samples From Patients With Indolent Systemic Mastocytosis (ISM) in the Phase 2 Pioneer Study Using a High Sensitivity Droplet Digital (dd) PCR Assay Compared With Next Generation Sequencing (NG","volume":"136","author":"George","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.anai.2021.06.021_bib0034","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.23672","article-title":"Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis","volume":"89","author":"Kristensen","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.anai.2021.06.021_bib0035","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","article-title":"Stem cell factor receptor\/c-kit: from basic science to clinical implications","volume":"92","author":"Lennartsson","year":"2012","journal-title":"Physiol Rev"},{"issue":"26","key":"10.1016\/j.anai.2021.06.021_bib0036","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.anai.2021.06.021_bib0037","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jaci.2020.03.044","article-title":"Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis","volume":"146","author":"Hartmann","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2021.06.021_bib0038","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaci.2018.06.003","article-title":"Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial","volume":"142","author":"van Anrooij","year":"2018","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2021.06.021_bib0039","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","article-title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial","volume":"21","author":"Heinrich","year":"2020","journal-title":"Lancet Oncol"},{"issue":"suppl 1","key":"10.1016\/j.anai.2021.06.021_bib0040","article-title":"Clinical activity in a phase 1 study of BLU-285, a potent, highly-selective inhibitor, of KIT D816V in advanced systemic mastocytosis (AdVSM)","volume":"130","author":"Deininger","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.anai.2021.06.021_bib0041","unstructured":"US National Library of Medicine. (Pathfinder) study to evaluate efficacy and safety of avapritinib (BLU-285), A selective KIT mutation-targeted tyrosine kinase inhibitor, in patients with advanced systemic mastocytosis. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03580655. Accessed March 15, 2021."},{"key":"10.1016\/j.anai.2021.06.021_bib0042","doi-asserted-by":"crossref","unstructured":"Akin C, Oude Elberink H, Gotlib JR, et\u00a0al. Pioneer part 2: a randomized, double-blind, placebo-controlled, phase 2 study to evaluate safety and efficacy of avapritinib in indolent systemic mastocytosis. Available at: https:\/\/www.blueprintmedicines.com\/wp-content\/uploads\/2020\/12\/Blueprint-Medicines-ASH-2020-Avapritinib-ISM-PIONEER-Trial-Part-2-Presentation.pdf. Accessed March 15, 2021.","DOI":"10.1182\/blood-2020-136632"},{"key":"10.1016\/j.anai.2021.06.021_bib0043","doi-asserted-by":"crossref","unstructured":"Akin C, Oude Elberink H, Gotlib JR, et\u00a0al. Pioneer: a randomized, double-blind, placebo-controlled, Phase 2 study of avapritinib in patients with indolent systemic mastocytosis. Available at: https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper139367.html. Accessed March 15, 2021.","DOI":"10.1016\/j.jaci.2019.12.062"},{"key":"10.1016\/j.anai.2021.06.021_bib0044","article-title":"Changes in mast cell numbers and phenotype in patients with indolent systemic mastocytosis treated with avapritinib","author":"George","year":"2021","journal-title":"AACR Annu Meet"},{"issue":"12","key":"10.1016\/j.anai.2021.06.021_bib0045","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.21894","article-title":"Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study","volume":"85","author":"Paul","year":"2010","journal-title":"Am J Hematol"},{"issue":"10069","key":"10.1016\/j.anai.2021.06.021_bib0046","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.anai.2021.06.021_bib0047","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10238-018-0541-2","article-title":"PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors","volume":"19","author":"Gebreyohannes","year":"2019","journal-title":"Clin Exp Med"},{"issue":"5","key":"10.1016\/j.anai.2021.06.021_bib0048","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ccell.2019.04.006","article-title":"Ripretinib (DCC-2618)is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants","volume":"35","author":"Smith","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.anai.2021.06.021_bib0049","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3324\/haematol.2017.179895","article-title":"The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis","volume":"103","author":"Schneeweiss","year":"2018","journal-title":"Haematologica"},{"issue":"15","key":"10.1016\/j.anai.2021.06.021_bib0050","article-title":"DCC-2618 is a potent inhibitor of wild-type and mutant KIT, including refractory Exon 17 D816 KIT mutations, and exhibits efficacy in refractory GIST and AML xenograft models","volume":"75","author":"Smith","year":"2015","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.anai.2021.06.021_bib0051","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3390\/biomedicines7010006","article-title":"Clinical activity and tolerability of SL-401 (Tagraxofusp): recombinant diphtheria toxin and interleukin-3 in hematologic malignancies","volume":"7","author":"Alkharabsheh","year":"2019","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.anai.2021.06.021_bib0052","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1128\/br.39.1.54-85.1975","article-title":"Diphtheria toxin: mode of action and structure","volume":"39","author":"Collier","year":"1975","journal-title":"Bacteriol Rev"},{"issue":"4","key":"10.1016\/j.anai.2021.06.021_bib0053","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/leu.2015.348","article-title":"CD123 immunostaining patterns in systemic mastocytosis: differential expression in disease subgroups and potential prognostic value","volume":"30","author":"Pardanani","year":"2016","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.anai.2021.06.021_bib0054","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1182\/blood.V128.22.4245.4245","article-title":"Results from ongoing Phase 2 trial of SL-401 in patients with advanced, high-risk myeloproliferative neoplasms including chronic myelomonocytic leukemia","volume":"128","author":"Patnaik","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.anai.2021.06.021_bib0055","unstructured":"Siebenhaar F, Bonnekoh H, Hawro T, et\u00a0al. Safety and efficacy data of AK002, an anti-Siglec-8 monoclonal antibody, in patients with indolent systemic mastocytosis (ISM): results from a first-in-human, open-label Phase 1 study. Available at: https:\/\/www.allakos.com\/file.cfm\/59\/docs\/Siebenhaar_et_al_EAACI_JUNE_2019.pdf. Accessed February 10, 2021."},{"issue":"2","key":"10.1016\/j.anai.2021.06.021_bib0056","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/s41385-020-00336-9","article-title":"A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation","volume":"14","author":"Schanin","year":"2021","journal-title":"Mucosal Immunol"},{"issue":"2","key":"10.1016\/j.anai.2021.06.021_bib0057","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000501637","article-title":"AK002, a humanized sialic acid-binding immunoglobulin-like Lectin-8 antibody that induces antibody-dependent cell-mediated cytotoxicity against human eosinophils and inhibits mast cell-mediated anaphylaxis in mice","volume":"180","author":"Youngblood","year":"2019","journal-title":"Int Arch Allergy Immunol"},{"issue":"17","key":"10.1016\/j.anai.2021.06.021_bib0058","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1056\/NEJMoa2012047","article-title":"Anti\u2013Siglec-8 antibody for eosinophilic gastritis and duodenitis","volume":"383","author":"Dellon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2021.06.021_bib0059","article-title":"CDX-0159, an anti-KIT monoclonal antibody, demonstrates dose-dependent reductions in plasma tryptase and a favorable safety profile in a Phase 1a healthy volunteer study","author":"Maurer","year":"2020","journal-title":"EAACI Annu Meet"},{"issue":"4","key":"10.1016\/j.anai.2021.06.021_bib0060","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1182\/bloodadvances.2017011080","article-title":"Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis","volume":"2","author":"Stone","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.anai.2021.06.021_bib0061","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaip.2013.09.004","article-title":"The mastocytosis society survey on mast cell disorders: patient experiences and perceptions","volume":"2","author":"Jennings","year":"2014","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120621004853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120621004853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:26:38Z","timestamp":1761053198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120621004853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S1081120621004853"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2021.06.021","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of systemic mastocytosis","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2021.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}